secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001628280-23-034537
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx announces FDA approval of XPHOZAH (tenapanor) for hyperphosphatemia in dialysis patients
--------------------------------------------------------------------------------

- FDA approved XPHOZAH to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy.
- Indicated for patients with inadequate response to phosphate binders or intolerant of any dose.
- XPHOZAH is a single tablet taken twice daily with a first-in-class mechanism blocking phosphate absorption.
- Approval date: October 17, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023034537/0001628280-23-034537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023034537/ardx-20231017.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-034537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer